Logo image of CERO

CERO THERAPEUTICS HOLDINGS I (CERO) Stock Fundamental Analysis

NASDAQ:CERO - Nasdaq - US71902K3032 - Common Stock - Currency: USD

9.23  -0.4 (-4.15%)

After market: 9.19 -0.04 (-0.43%)

Fundamental Rating

0

CERO gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 555 industry peers in the Biotechnology industry. CERO has a bad profitability rating. Also its financial health evaluation is rather negative. CERO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CERO had negative earnings in the past year.
In the past year CERO has reported a negative cash flow from operations.
CERO Yearly Net Income VS EBIT VS OCF VS FCFCERO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -500K -1M -1.5M -2M -2.5M

1.2 Ratios

CERO has a Return On Assets of -142.62%. This is amonst the worse of the industry: CERO underperforms 84.50% of its industry peers.
Industry RankSector Rank
ROA -142.62%
ROE N/A
ROIC N/A
ROA(3y)-10.46%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CERO Yearly ROA, ROE, ROICCERO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 20 -20 40 -40

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CERO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CERO Yearly Profit, Operating, Gross MarginsCERO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

0

2. Health

2.1 Basic Checks

CERO has about the same amout of shares outstanding than it did 1 year ago.
Compared to 1 year ago, CERO has a worse debt to assets ratio.
CERO Yearly Shares OutstandingCERO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 5M 10M 15M 20M
CERO Yearly Total Debt VS Total AssetsCERO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 50M 100M 150M

2.2 Solvency

CERO has an Altman-Z score of -19.47. This is a bad value and indicates that CERO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CERO (-19.47) is worse than 84.86% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -19.47
ROIC/WACCN/A
WACCN/A
CERO Yearly LT Debt VS Equity VS FCFCERO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 0.39 indicates that CERO may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.39, CERO is doing worse than 93.15% of the companies in the same industry.
CERO has a Quick Ratio of 0.39. This is a bad value and indicates that CERO is not financially healthy enough and could expect problems in meeting its short term obligations.
CERO has a Quick ratio of 0.39. This is amonst the worse of the industry: CERO underperforms 92.79% of its industry peers.
Industry RankSector Rank
Current Ratio 0.39
Quick Ratio 0.39
CERO Yearly Current Assets VS Current LiabilitesCERO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

CERO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -106.14%.
EPS 1Y (TTM)-106.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CERO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.08% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2Y25.03%
EPS Next 3Y24.9%
EPS Next 5Y18.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CERO Yearly EPS VS EstimatesCERO Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 -50 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CERO. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CERO Price Earnings VS Forward Price EarningsCERO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CERO Per share dataCERO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -200 -400 -600

4.3 Compensation for Growth

CERO's earnings are expected to grow with 24.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.03%
EPS Next 3Y24.9%

More info and screens

0

5. Dividend

5.1 Amount

CERO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CERO THERAPEUTICS HOLDINGS I

NASDAQ:CERO (7/1/2025, 9:34:48 PM)

After market: 9.19 -0.04 (-0.43%)

9.23

-0.4 (-4.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)N/A N/A
Inst Owners9.39%
Inst Owner Change12992.6%
Ins Owners8.34%
Ins Owner Change0%
Market Cap71.26M
Analysts80
Price Target61.2 (563.06%)
Short Float %N/A
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)445.46%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-623.5
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.5
FCFYN/A
OCF(TTM)-1.5
OCFYN/A
SpS0
BVpS-0.48
TBVpS-0.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -142.62%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-10.46%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.39
Quick Ratio 0.39
Altman-Z -19.47
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-106.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.84%
EPS Next YN/A
EPS Next 2Y25.03%
EPS Next 3Y24.9%
EPS Next 5Y18.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-275.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-716.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-716.44%
OCF growth 3YN/A
OCF growth 5YN/A